NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Methyl inosine monophosphate (MIMP) restores HIV-associated suppression of the proliferative responses of human lymphocytes in vitro.

Hadden JW, Ongradi J, Specter S, Nelson R, Hadden E, Sosa M, Strand M, Monell P; International Conference on AIDS.

Int Conf AIDS. 1991 Jun 16-21; 7: 105 (abstract no. W.A.1052).

Department of Medicine, University of South Florida Medical College, Tampa, Florida, USA

OBJECTIVE: The present study was designed to determine whether MIMP, a new thymomimetic purine, could reverse HIV-induced immune suppression in vitro. METHODS: Lymphocytes were obtained from 8 patients with acquired immunodeficiency disease (AIDS), 8 with symptomatic pre-AIDS (ARC), and 8 normals controls and were stimulated in vitro with phytohemagglutinin (PHA). RESULTS: AIDS patients (mean CD4 counts of 44) showed PHA responses less than 10% of control while ARC patients (mean CD4 counts of 444) showed responses approximately 50% of the control responses. MIMP (0.1, 1, 10 and 100 ug/ml) progressively augmented the PHA responses in all these groups. The augmentation of the responses of the leukocytes of AIDS patients while statistically significant was minimal. The augmentation of the responses of the ARC patients was significant and their maximal responses approached control levels. The effect of 1 ug/ml MIMP was comparable to that observed with indomethacin (10(-6)M) and interleukin 2 (IL2 - 4 units/ml) and was additive with each of these stimulants. In a parallel manner, MIMP reversed the suppression of control lymphocytes induced by the immunosuppressive 17 amino acid fragment of the P41 peptide of HIV. DISCUSSION-CONCLUSION: Preliminary experiments also indicate that MIMP delays death in a murine FLV AIDS model with low but not high dose virus inoculation. MIMP is under development for early human HIV disease.

Publication Types:
  • Meeting Abstracts
Keywords:
  • AIDS Vaccines
  • AIDS-Related Complex
  • Acquired Immunodeficiency Syndrome
  • Animals
  • Antigens, CD4
  • HIV
  • HIV Envelope Protein gp120
  • HIV Infections
  • HIV Seropositivity
  • Humans
  • Immunosuppressive Agents
  • In Vitro
  • Indomethacin
  • Inosine Monophosphate
  • Interleukin-2
  • Lymphocytes
  • Phytohemagglutinins
  • immunology
  • methyl inosine monophosphate
Other ID:
  • 3105291
UI: 102192244

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov